Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Advanced cancer pain refers to severe, persistent pain in advanced malignancies caused by tumor progression, nerve involvement, and treatment-related complications. According to Sarkar, Shima Rani et al., 2025, globally, about 35% to 96% of advanced cancer patients experience pain in the terminal phase, with variation across care settings. As per the advanced cancer pain management pipeline analysis by Expert Market Research, the cancer pain pipeline includes opioid alternatives for cancer pain, non-opioid cancer analgesics, the breakthrough cancer pain (BTcP) pipeline, and refractory cancer pain therapeutics, advancing oncology pain management drug development. Growing focus on multimodal, targeted therapies is expected to improve outcomes and expand treatment options in the coming years.
-
Major companies involved in the advanced cancer pain management pipeline analysis include Cy Biopharma, Telix Pharmaceuticals (Innovations) Pty Limited, and others.
-
Leading drugs currently in the pipeline include Psilocybin, 153Sm-DOTMP, Intrathecal Resiniferatoxin, and others.
-
The pipeline includes growth in bone metastasis pain pipeline, chemotherapy-induced peripheral neuropathy (CIPN) drugs, and end-of-life pain management innovation, alongside advancements in neurolytic procedures and pharmacotherapy for improved control of refractory cancer-related pain.
Report Coverage
The Advanced Cancer Pain Management Pipeline Analysis Report by Expert Market Research gives comprehensive insights into advanced cancer pain management therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced cancer pain management. The advanced cancer pain management report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced cancer pain management pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with advanced cancer pain management treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced cancer pain management.
Read more about this report - Request a Free Sample
Advanced Cancer Pain Management Drug Pipeline Outlook
Advanced cancer pain management involves the assessment and treatment of persistent pain caused by tumor growth, nerve compression, bone metastasis, or cancer therapies. The condition commonly occurs in late-stage malignancies and significantly affects physical functioning and quality of life. Management approaches focus on reducing pain intensity, improving comfort, and supporting long-term symptom control through pharmacological and supportive care strategies.
Advanced cancer pain management treatment includes opioid and non-opioid therapies, nerve-targeted medications, and interventional approaches. Drugs such as Oxycodone, Methadone, Tramadol, Ziconotide (Prialt), and Fentanyl (Subsys, Abstral) are recommended under NCCN Adult Cancer Pain Guidelines and ASCO supportive care protocols for severe cancer-related pain management. In September 2025, experts highlighted buprenorphine as a safer opioid alternative in the cancer pain management drug pipeline due to its lower sedation and overdose risk. The discussion supported broader adoption alongside therapies such as Tapentadol (Nucynta) and investigational agents, including Cebranopadol and Suzetrigine (Vertex Pharmaceuticals) for refractory cancer pain treatment.
Advanced Cancer Pain Management Epidemiology
The increasing incidence of advanced and metastatic cancer is driving significant focus on the advanced cancer supportive care drug pipeline. According to Sarkar, Shima Rani et al., 2025, pain affects 35% to 96% of patients in terminal cancer stages, while 66% of patients at metastatic or end-stage disease experience persistent pain. In addition, Ellis Slotman et al., 2026 reported that nearly 45% of cancer patients experience pain, with up to 40% suffering from moderate to severe pain. The rising cases of breakthrough pain and end-of-life pain management needs are encouraging the development of targeted analgesics, opioid alternatives, and supportive therapies in the pipeline.
Advanced Cancer Pain Management – Pipeline Therapeutic Assessment
This section of the report covers the analysis of advanced cancer pain management drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The advanced cancer pain management pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Advanced Cancer Pain Management Drug Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total advanced cancer pain management clinical trials, holds 67% share, reflecting strong early-stage development activity and increasing focus on innovative pain therapies. Phase II accounts for 33%, highlighting continued clinical evaluation and therapeutic advancement. The growing concentration in these phases is expected to support future treatment innovation, improve pain management outcomes, and strengthen overall market growth.
Advanced Cancer Pain Management Drug Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the advanced cancer pain management pipeline analysis include small. The advanced cancer pain management report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced cancer pain management. Advanced cancer pain management pipelines are witnessing the development of emerging non-opioid therapies for refractory cancer pain with improved safety and targeted analgesic activity. Resiniferatoxin (RTX), a transient receptor potential vanilloid 1 agonist, is being evaluated in late-stage oncology pain clinical trials for opioid-refractory cancer pain. Such candidates highlight novel mechanisms of action for cancer pain pipeline development by selectively targeting pain-sensing neurons while preserving motor and sensory functions.
Advanced Cancer Pain Management Clinical Trials – Key Players
The EMR report for the advanced cancer pain management pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed advanced cancer pain management therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in advanced cancer pain management clinical trials:
- Cy Biopharma
- Telix Pharmaceuticals (Innovations) Pty Limited
- ZYUS Life Sciences
- Sorrento Therapeutics, Inc.
- Quintiles, Inc.
- GW Pharmaceuticals Ltd.
- Jazz Pharmaceuticals
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Advanced Cancer Pain Management – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for advanced cancer pain management. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced cancer pain management drug candidates.
Drug: Psilocybin
Psilocybin, a naturally derived tryptamine psychedelic acting on serotonin 5-HT2A receptors in the central nervous system, is being evaluated in a Phase II clinical study for advanced cancer pain management. The study is being sponsored by Yvan Beaussant at the Dana-Farber Cancer Institute, with support from Filament Health for investigational drug supply. It is examining whether psilocybin-assisted therapy, administered orally under controlled conditions with psychotherapy support, can reduce opioid-refractory pain by modulating mood, inflammation, and pain perception. The study is expected to complete by December 2026 and is also assessing reductions in opioid requirements and improvements in psychological distress.
Drug: 153Sm-DOTMP
153Sm-DOTMP (CycloSam®), a radiopharmaceutical bone-seeking chelator complex developed by Telix Pharmaceuticals (Innovations) Pty Limited, is being evaluated in a Phase I SOLACE study for the treatment of advanced cancer-related bone pain. The drug is a samarium-153–labelled DOTMP compound administered as a single intravenous dose, designed to selectively localize in metastatic bone lesions and deliver targeted beta radiation for long-lasting analgesia. The study is examining safety, pharmacokinetics, radiation dosimetry, dose optimization, and preliminary pain relief outcomes in patients with bone metastases. The trial is expected to be completed by July 2027, focusing on optimizing therapeutic efficacy while minimizing hematologic toxicity.
Drug: Intrathecal Resiniferatoxin
Resiniferatoxin is being investigated as a potent, non-opioid analgesic for advanced cancer pain management in a Phase I, open-label, dose-escalation study sponsored by the National Institute of Dental and Craniofacial Research under the National Institutes of Health Clinical Center. The study is examining the safety, tolerability, and analgesic efficacy of intrathecal resiniferatoxin, a highly selective transient receptor potential vanilloid 1 agonist derived from cactus-like plants, which irreversibly ablates nociceptive neurons that transmit chronic pain. The drug is being administered via spinal catheter under controlled hospital conditions. The trial is expected to be completed by February 2027 while evaluating pain reduction and opioid-sparing effects in refractory cancer pain patients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Advanced Cancer Pain Management Drug Pipeline Insight Report
- Which companies/institutions are leading the advanced cancer pain management drug development?
- Which company is leading the advanced cancer pain management pipeline development activities?
- What is the current advanced cancer pain management commercial assessment?
- What are the opportunities and challenges present in the advanced cancer pain management pipeline landscape?
- What is the efficacy and safety profile of advanced cancer pain management pipeline drugs?
- Which company is conducting major trials for advanced cancer pain management drugs?
- Which companies/institutions are involved in advanced cancer pain management collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in advanced cancer pain management?
Reasons To Buy This Report
The Advanced Cancer Pain Management pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for advanced cancer pain management. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into advanced cancer pain management collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
